Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECTOR: Temozolomide Rechallenge in Glioblastoma
NCT00941460Phase 2Completed
- Sponsor
- Prof. Dr. Wolfgang Wick
- Start
- Sep 2009
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Prof. Dr. Wolfgang Wick. Primary endpoint: Median Time to Treatment Failure at 1 year. Started Sep 2009; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00941460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941460.